Related Experiment Video
Updated: Jan 21, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model
Takashi Higuchi1,2,3, Norihiko Sugisawa1,2, Kentaro Miyake1,2
1AntiCancer, Inc., San Diego, CA, U.S.A.
Background/Aim:
Recurrent osteosarcoma is a recalcitrant disease; therefore, an improved strategy is urgently needed to provide therapy. In order to develop a novel strategy for this disease, our lab has developed a patient-derived orthotopic xenograft (PDOX) mouse model for osteosarcoma. The combination of sorafenib (SFN) and palbociclib (PAL) was shown to be effective of hepatocellular carcinoma. However, whether this combination is efficacious on osteosarcoma has not been reported. The aim of this study was to determine the efficacy of the SFN and PAL combination on a cisplatinum (CDDP)-resistant osteosarcoma PDOX model.
Materials And Methods:
Osteosarcoma PDOX models were randomly divided into five treatment groups: untreated-control, CDDP, SFN, PAL and the combination of SFN and PAL.
Results:
Of these agents, the SFN-PAL combination significantly regressed tumor growth, and enhanced tumor necrosis with degenerative changes in the osteosarcoma PDOX.
Conclusion:
The SFN-PAL combination is an effective treatment strategy for osteosarcoma and therefore holds promise for clinical efficacy.
Insights
The combination of sorafenib (SFN) and palbociclib (PAL) effectively treated osteosarcoma in a preclinical model. This novel strategy significantly reduced tumor growth and increased necrosis in cisplatinum-resistant osteosarcoma.
Area of Science:
- Oncology
- Pharmacology
- Preclinical Research
Background:
- Recurrent osteosarcoma presents a significant therapeutic challenge, necessitating novel treatment strategies.
- Patient-derived orthotopic xenograft (PDOX) models are crucial for developing effective osteosarcoma therapies.
- The efficacy of sorafenib (SFN) and palbociclib (PAL) combination in osteosarcoma remains unexplored.
Purpose of the Study:
- To evaluate the therapeutic efficacy of the SFN and PAL combination.
- To assess the SFN and PAL combination in a cisplatinum (CDDP)-resistant osteosarcoma PDOX model.
Main Methods:
- Osteosarcoma PDOX models were established.
- Models were randomized into five groups: control, CDDP, SFN, PAL, and SFN + PAL combination.
- Tumor growth and necrosis were assessed.
Main Results:
- The SFN + PAL combination significantly inhibited osteosarcoma tumor growth in PDOX models.
- Enhanced tumor necrosis and degenerative changes were observed with the SFN + PAL combination.
- The combination demonstrated superior efficacy compared to individual agents or CDDP.
Conclusions:
- The SFN + PAL combination represents a promising therapeutic strategy for osteosarcoma.
- This combination therapy holds potential for clinical application in treating osteosarcoma, particularly resistant forms.
Related Concept Videos
Regression Toward the Mean
Multiple Regression
Farmers can use multiple regression to determine the crop yield based on more than one factor, such as water availability, fertilizer, soil properties, etc. Here, the crop yield is the response or dependent variable as it depends on the other independent variables. The analysis requires the construction of a scatter plot...
Correlation and Regression
Regression Analysis
In regression analysis, a regression equation is determined based on the line of best fit– a line that best fits the data points plotted in a graph. This line is also called the regression line. The algebraic equation for the regression line is called the regression equation. It is represented as:
Microsoft Excel: Regression Analysis
To perform regression...
Resistivity

